# Surufatinib and Sintilimab in Combination With Capecitabine for Metastatic Adenocarcinoma of Small Intestine or Appendix Carcinoma

> **NCT05472948** · PHASE2 · RECRUITING · sponsor: **Sun Yat-sen University** · enrollment: 36 (estimated)

## Conditions studied

- Adenocarcinoma of Small Intestine
- Appendix Carcinoma
- Metastatic

## Interventions

- **DRUG:** Surufatinib
- **DRUG:** Sintilimab
- **DRUG:** Capecitabine

## Key facts

- **NCT ID:** NCT05472948
- **Lead sponsor:** Sun Yat-sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-02-01
- **Primary completion:** 2027-12-30
- **Final completion:** 2027-12-30
- **Target enrollment:** 36 (ESTIMATED)
- **Last updated:** 2025-12-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05472948

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05472948, "Surufatinib and Sintilimab in Combination With Capecitabine for Metastatic Adenocarcinoma of Small Intestine or Appendix Carcinoma". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT05472948. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*